Document ID: chunk:federal_register_of_legislation:F2025L00069:schedule:1
Version: federal_register_of_legislation:F2025L00069
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2037–3240

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

 1.         Schedule 1, after item dealing with Alemtuzumab
    Omit:
         Alirocumab

 1.         Schedule 1, after item dealing with Dapagliflozin
    Omit:
         Dapsone

 1.         Schedule 1, after item dealing with Glucose and ketone indicator urine
    Omit:
         Glucose indicator—urine

 1.         Schedule 1, after item dealing with Mannitol
    Omit:
         Maraviroc

 1.         Schedule 1, after item dealing with Ozanimod
    Omit:
         Paclitaxel, nanoparticle albumin‑bound

 1.         Schedule 1, after item dealing with Selinexor
    Insert:
         Selpercatinib

 1.         Schedule 1, after item dealing with Tiagabine
    Omit:
         Ticagrelor

 1.         Schedule 2, after item dealing with Dabigatran etexilate
    Insert:
         Dapsone

 1.         Schedule 2, after item dealing with Macrogol 3350
    Insert:
         Maraviroc

 1.    Schedule 2, after item dealing with Paclitaxel
    Insert:
         Paclitaxel, nanoparticle albumin‑bound

 1.    Schedule 2, after item dealing with Tetrabenazine
    Insert:
         Ticagrelor